ISSN: 2835-7914

Research Article

Biomedical Science and Clinical Research

From Traditional Medicine to Modern Drug Development: Natural Products Targeting Amyloid Plaque in Alzheimer's Disease

Ali Rahmani[1]* and Maedeh Dahaghin[2]

[1]*Department of Pharmaceutical Biomaterials, Tehran University of Medical Sciences, Tehran, Iran*

[2]*Department of Medicinal Chemistry, Tehran University of Medical Sciences, Tehran, Iran*

***Corresponding Author**
Ali Rahmani, Department of Pharmaceutical Biomaterials, Tehran University of Medical Sciences, Tehran, Iran.

Submitted: 2023, June 13 **Accepted:** 2023, July 12 **Published:** 2023, July 17

Citation: Rahmani, A., Dahaghim, M. (2023). From Traditional Medicine to Modern Drug Development: Natural Products Targeting Amyloid Plaque in Alzheimer's Disease. *Biomed Sci Clin Res, 2*(3), 270-274.

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder that affects millions of people worldwide, and its pathogenesis is characterized by the formation of amyloid plaque in the brain. Current treatments for AD are limited and only offer symptomatic relief, making the development of new therapies a crucial area of research. One promising approach is the use of natural products, which have been used in traditional medicine for centuries and are a rich source of bioactive compounds. In this review, we discuss the use of natural products for the treatment of AD, with a particular focus on those that target amyloid plaque formation and clearance. We highlight the mechanisms of action of these natural products, including inhibition of amyloid-beta (Aβ) aggregation, promotion of Aβ degradation, and modulation of Aβ-induced neuroinflammation. We also discuss the challenges associated with the development of natural products as therapeutics, including issues related to standardization, quality control, and safety. Finally, we examine the potential of combining natural products with modern drug development approaches, such as nanotechnology and synthetic biology, to overcome these challenges and develop effective treatments for AD.

Keywords: Alzheimer's Disease, Natural Products, Amyloid Plaque, Drug Development, Nanotechnology, Synthetic Biology

1. Introduction

Alzheimer's disease is a neurodegenerative disorder that affects millions of people worldwide, and is characterized by progressive cognitive decline and memory loss. One of the key pathological features of Alzheimer's disease is the accumulation of amyloid plaque in the brain, which is composed primarily of aggregated beta-amyloid peptides [1]. These plaques are thought to contribute to the neurodegenerative process in Alzheimer's disease by disrupting normal brain function and leading to the death of brain cells. Currently, there are no effective treatments that can slow or halt the progression of Alzheimer's disease, and most therapies are focused on managing symptoms [2]. This highlights the urgent need for new therapeutic approaches that can address the underlying pathological mechanisms of the disease, including the formation of amyloid plaque in the brain. Natural products, including plant-derived compounds, have long been used in traditional medicine for the treatment of various ailments. In recent years, there has been increasing interest in the potential of natural products as a source of new drug leads for a wide range of diseases, including Alzheimer's disease. Several natural products have been shown to have activity against amyloid plaque formation, either by inhibiting the aggregation of beta-amyloid peptides or by promoting their clearance from the brain [3]. These compounds offer the advantage of being generally safe and well-tolerated, with many having been used for centuries in traditional medicine. In this review article, we will explore the potential of natural products as a source of new drug leads for the treatment of Alzheimer's disease, with a particular focus on compounds that target the formation and clearance of amyloid plaque in the brain. We will also discuss the challenges and opportunities associated with the development of natural products as therapeutics for Alzheimer's disease, including issues related to pharmacokinetics, bioavailability, and efficacy.

2. Natural Products Targeting Amyloid Plaque in Alzheimer's Disease

A. Inhibition of Aβ aggregation

3. Curcumin

Curcumin is a natural polyphenol compound found in turmeric, a commonly used spice in traditional Indian medicine. Curcumin has been shown to have a variety of biological activities, including anti-inflammatory, antioxidant, and anticancer effects [4]. More recently, curcumin has emerged as a potential therapeutic agent for Alzheimer's disease (AD), due to its ability to inhibit the aggregation of amyloid-beta (Aβ) peptides, which is a hallmark feature of the disease. Several in vitro and in vivo studies have demonstrated that curcumin can prevent the formation of Aβ oligomers and fibrils, which are thought to be the toxic species that contribute to AD pathology [5]. Curcumin has been shown to bind to Aβ peptides and disrupt their aggregation, as well as promote their clearance by microglia, the immune cells

in the brain that are responsible for removing damaged cells and debris. In addition to its direct effects on Aβ aggregation, curcumin has also been shown to have other beneficial effects on AD pathology, including reducing inflammation, oxidative stress, and tau hyperphosphorylation, which are all key features of the disease [6]. Furthermore, curcumin has been found to improve cognitive function and memory in animal models of AD, although its efficacy in human studies is still uncertain.

4. Epigallocatechin-3-Gallate

Epigallocatechin-3-gallate (EGCG) is a flavonoid compound found in green tea that has been shown to have potential therapeutic effects in the treatment of Alzheimer's disease (AD). One mechanism by which EGCG may exert its beneficial effects is through inhibition of amyloid beta (Aβ) aggregation [7]. Studies have shown that EGCG can bind to Aβ peptides and inhibit their aggregation into larger amyloid fibrils, which are a hallmark feature of AD. EGCG has been found to interact with specific amino acid residues in the Aβ peptide, preventing their self-assembly and promoting the formation of smaller, less toxic oligomers. In addition to its direct effects on Aβ aggregation, EGCG has been shown to have antioxidant and anti-inflammatory properties that may also contribute to its neuroprotective effects in AD. EGCG has been shown to reduce oxidative stress and inflammation in the brain, which are thought to contribute to the pathogenesis of AD. While EGCG has shown promise in preclinical studies, its potential as a therapeutic agent for AD in humans is still being investigated. Challenges to the use of EGCG in clinical trials include issues with bioavailability, dosing, and potential adverse effects at higher doses. However, ongoing research continues to explore the potential therapeutic benefits of EGCG and other natural products in the treatment of AD [8].

5. Resveratrol

Resveratrol is a natural polyphenol found in various plants, including grapes, berries, and peanuts. It has been investigated for its potential therapeutic benefits in various diseases, including Alzheimer's disease (AD), which is characterized by the accumulation of amyloid beta (Aβ) plaques in the brain. Resveratrol has been shown to inhibit the formation and promote the disaggregation of Aβ in vitro and in animal models of AD [9]. Studies have shown that resveratrol can prevent the formation of Aβ oligomers and fibrils, which are thought to be the toxic forms of Aβ. Resveratrol has also been shown to promote the degradation of existing Aβ aggregates and enhance Aβ clearance from the brain. In addition to its anti-amyloidogenic effects, resveratrol has been shown to possess other neuroprotective properties, such as anti-inflammatory, antioxidant, and antiapoptotic effects [10]. These properties may contribute to its potential therapeutic benefits in AD. Despite promising results in preclinical studies, clinical trials investigating the efficacy of resveratrol in AD have shown mixed results. Some studies have reported improvements in cognitive function and biomarkers of AD pathology, while others have shown no significant effects [11]. Further research is needed to elucidate the mechanisms underlying the potential therapeutic effects of resveratrol in AD and to optimize its use in the clinical setting.

6. Promotion of Aβ Degradation

6.1 Bacopa Monnieri

Bacopa monnieri is a perennial herb commonly known as Brahmi, which has been traditionally used in Ayurveda to enhance cognitive function and memory. Recent studies have shown that *Bacopa monnieri* extract (BME) has potential as a therapeutic agent for Alzheimer's disease due to its ability to promote the degradation of amyloid beta (Aβ) protein aggregates [12]. BME has been shown to activate the proteasomal degradation pathway, which is responsible for breaking down Aβ aggregates. A study conducted on transgenic mice models of Alzheimer's disease found that BME treatment increased the levels of proteasome subunits, leading to a reduction in Aβ levels and improved cognitive function. Furthermore, BME has been shown to enhance the expression and activity of neprilysin, an enzyme responsible for degrading Aβ in the brain [13]. Studies conducted on rat models of Alzheimer's disease found that BME treatment increased the expression and activity of neprilysin, leading to a reduction in Aβ levels and improved cognitive function. Overall, these findings suggest that *Bacopa monnieri* may have potential as a therapeutic agent for Alzheimer's disease by promoting the degradation of Aβ aggregates through activation of the proteasomal degradation pathway and enhancement of neprilysin activity [14].

7. Huperzine A

Huperzine A is a natural compound that has been traditionally used in Chinese medicine for the treatment of memory deficits. It is an acetylcholinesterase inhibitor, which means that it enhances the activity of acetylcholine, an important neurotransmitter in the brain. Huperzine A has been shown to have neuroprotective effects and to improve cognitive function in animal models and human clinical studies [15]. In addition to its cholinergic effects, Huperzine A has also been found to promote the degradation of Aβ. One study found that Huperzine A could reduce Aβ levels in the brains of rats with Alzheimer's disease-like symptoms, and this effect was associated with an increase in the activity of neprilysin, an enzyme that degrades Aβ [16]. Another study investigated the effects of Huperzine A on Aβ levels in the brains of mice that were genetically engineered to develop Alzheimer's disease-like symptoms. The study found that treatment with Huperzine A led to a significant reduction in Aβ levels in the brain, and this effect was associated with an increase in the activity of the enzyme insulin-degrading enzyme (IDE), which is involved in the degradation of Aβ. These findings suggest that Huperzine A may be a promising natural compound for the treatment of Alzheimer's disease by promoting the degradation of Aβ [17]. However, more research is needed to fully understand the mechanisms underlying its effects and to determine its efficacy and safety in human clinical studies.

8. Ginkgo Biloba

There is some evidence to suggest that Ginkgo biloba, a traditional Chinese medicine, may promote the degradation of amyloid beta. In vitro studies have shown that ginkgolides, compounds found in Ginkgo biloba, can inhibit the formation of amyloid beta and promote its degradation by increasing the activity of neprilysin, an enzyme that degrades amyloid beta [18]. In addition, a study found that a standardized extract of

Ginkgo biloba was able to decrease the levels of amyloid beta in the brains of mice with Alzheimer's disease. The extract also improved cognitive function in the mice [19]. However, more research is needed to determine the effectiveness of Ginkgo biloba in promoting Aβ degradation in humans. Clinical studies have produced mixed results, with some showing a benefit and others showing no effect.

9. Modulation of Aβ-Induced Neuroinflammation

9.1 Salvia Miltiorrhiza

Salvia miltiorrhiza, also known as Danshen, is a traditional Chinese medicine herb that has been shown to have neuroprotective effects. Studies have suggested that it may also have potential in the modulation of Aβ-induced neuroinflammation [20]. One study investigated the effect of *Salvia miltiorrhiza* on microglial activation and neuroinflammation induced by Aβ. The results showed that *Salvia miltiorrhiza* treatment reduced the expression of pro-inflammatory cytokines and chemokines, and decreased the activation of microglia in the brain [21]. Another study found that *Salvia miltiorrhiza* reduced neuroinflammation and oxidative stress in a mouse model of Alzheimer's disease. These findings suggest that *Salvia miltiorrhiza* may have potential in the modulation of Aβ-induced neuroinflammation, and further research is needed to explore its therapeutic potential in Alzheimer's disease [22].

10. Panax Ginseng

Panax ginseng has been found to have anti-inflammatory and antioxidant effects, which make it a promising candidate for modulating Aβ-induced neuroinflammation. Studies have shown that treatment with Panax ginseng extracts can reduce inflammation and oxidative stress in animal models of Alzheimer's disease, resulting in improved cognitive function [23]. In addition, Panax ginseng has been shown to have a protective effect on neuronal cells, reducing their vulnerability to Aβ-induced damage. Therefore, Panax ginseng may have potential as a therapeutic agent for Alzheimer's disease by targeting Aβ-induced neuroinflammation [24].

11. Withania Somnifera

Several studies have reported the neuroprotective effects of Withania somnifera, also known as Ashwagandha, against Aβ-induced neuroinflammation in Alzheimer's disease. Withaferin A, a major bioactive compound found in Withania somnifera, has been found to reduce the expression of pro-inflammatory cytokines and inhibit microglial activation induced by Aβ [25]. Withaferin A also enhances the expression of anti-inflammatory cytokines and promotes the phagocytic activity of microglia to clear Aβ. These effects of Withaferin A on neuroinflammation and Aβ clearance have been attributed to its antioxidant and anti-inflammatory properties. Thus, Withania somnifera holds potential as a natural product for the modulation of Aβ-induced neuroinflammation in Alzheimer's disease [26].

12. Challenges Associated with the Development of Natural Products as Therapeutics

12.1 Standardization

Standardization is an essential aspect of drug development, ensuring consistent quality and safety of the final product. In the case of natural products, standardization poses unique challenges due to the inherent variability of the source materials. These challenges include variability in plant growth conditions, extraction methods, and chemical composition, among others [27]. For example, different strains of the same plant species or different parts of the same plant may have varying concentrations of active compounds. Extraction methods can also affect the concentration of the active compounds, and contamination with other substances can occur during the production process. Additionally, natural products may interact with other medications or exhibit unpredictable effects due to individual genetic differences [28]. To address these challenges, various standardization methods have been proposed, including the use of reference compounds, phytochemical profiling, and bioassays. Standardization can also involve the development of strict quality control measures and manufacturing processes to ensure consistency and purity of the final product. Overall, the challenges associated with standardizing natural products highlight the need for careful selection, characterization, and standardization of source materials to optimize their potential as therapeutic agents [29].

12.2 Quality Control

Quality control is a critical aspect of natural product development as it ensures the safety, efficacy, and consistency of the product. However, it poses significant challenges in the development of natural products as therapeutics. One major challenge is the lack of standardization in natural product manufacturing, which can lead to variations in the chemical composition and potency of the product. This is especially true for herbal medicines, where the chemical constituents can vary depending on several factors such as the geographical location, time of harvest, and storage conditions [30]. Another challenge is the difficulty in ensuring the purity of natural products, which may be contaminated with toxic substances or adulterated with synthetic compounds. This can result in unexpected side effects or reduced therapeutic efficacy. Moreover, there is a lack of standardized analytical methods for natural products, which makes it challenging to assess their quality and purity. To address these challenges, regulatory bodies have implemented guidelines and standards for natural product development, such as the Good Manufacturing Practice (GMP) and the United States Pharmacopeia (USP) standards. These guidelines aim to ensure the safety, quality, and efficacy of natural products by establishing standardized manufacturing processes, quality control procedures, and analytical methods [31]. Overall, while natural products have promising therapeutic potential, their development as therapeutics poses significant challenges in ensuring their safety, efficacy, and consistency. Therefore, it is essential to establish standardized manufacturing processes, quality control procedures, and analytical methods to ensure the quality and purity of natural products.

12.3 Safety

The use of natural products as therapeutics presents several challenges related to safety. Unlike synthetic drugs, natural products have complex chemical compositions, making it difficult to identify the active ingredient and potential toxic components. Natural products can also interact with other medications and have unpredictable effects on the body. Additionally, natural products can be contaminated with heavy metals, pesticides, or other toxins, which can cause adverse effects [32]. To

ensure the safety of natural products, rigorous quality control and safety testing should be conducted. This includes testing for contaminants, assessing toxicity, and evaluating potential drug interactions. It is also important to follow proper dosage and administration guidelines, as well as to monitor patients closely for any adverse effects. Despite these challenges, natural products have shown promise as therapeutics for a range of conditions, and continued research and development can help to address safety concerns and improve the efficacy of these treatments [33].

13. Combining Natural Products with Modern Drug Development Approaches

Combining natural products with modern drug development approaches has the potential to enhance the efficacy and safety of natural products as therapeutics. Nanotechnology and synthetic biology are two promising approaches that can be used to overcome some of the challenges associated with the development of natural products. Nanotechnology can be used to enhance the delivery of natural products to specific target sites and improve their bioavailability [34]. Synthetic biology can be used to engineer natural products for improved activity, stability, and selectivity. By combining these approaches with traditional drug development methods, natural products can be developed into safe and effective therapeutics for a variety of diseases, including those associated with amyloid plaque [35]. However, there are also challenges associated with the use of nanotechnology and synthetic biology in natural product development, including regulatory hurdles and ethical concerns.

14. Conclusion

Alzheimer's disease (AD) is a devastating neurodegenerative disorder with no cure. The accumulation of amyloid beta (Aβ) plaques is a key hallmark of AD pathology, and strategies targeting Aβ have been a major focus of drug development. Natural products have shown promising potential in targeting Aβ aggregation, promoting Aβ degradation, and modulating Aβ-induced neuroinflammation. However, the development of natural products as therapeutics poses challenges in terms of standardization, quality control, and safety. To overcome these challenges, modern drug development approaches such as nanotechnology and synthetic biology can be combined with natural products. Nanoparticles can enhance the bioavailability and efficacy of natural products, while synthetic biology can enable the production of complex natural products and facilitate their modification. Future research should focus on identifying novel natural products with potent activity against Aβ, optimizing their pharmacological properties, and conducting rigorous clinical trials to establish their safety and efficacy. Additionally, there is a need to investigate the mechanisms underlying the beneficial effects of natural products in AD and their potential synergistic effects with existing drugs. In conclusion, natural products have great potential for the treatment of AD, and their combination with modern drug development approaches can address the challenges associated with their development as therapeutics. Further research in this area can lead to the development of effective and safe natural product-based therapies for AD and other neurodegenerative disorders.

References

1. Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985). Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proceedings of the National Academy of Sciences, 82(12), 4245-4249.
2. Liu, Z., Zhang, A., Sun, H., Han, Y., Kong, L., & Wang, X. (2017). Two decades of new drug discovery and development for Alzheimer's disease. RSC advances, 7(10), 6046-6058.
3. Williams, P., Sorribas, A., & Howes, M. J. R. (2011). Natural products as a source of Alzheimer's drug leads. Natural product reports, 28(1), 48-77.
4. Hamaguchi, T., Ono, K., & Yamada, M. (2010). Curcumin and Alzheimer's disease. CNS neuroscience & therapeutics, 16(5), 285-297.
5. Monroy, A., Lithgow, G. J., & Alavez, S. (2013). Curcumin and neurodegenerative diseases. Biofactors, 39(1), 122-132.
6. Pandey, N., Strider, J., Nolan, W. C., Yan, S. X., & Galvin, J. E. (2008). Curcumin inhibits aggregation of α-synuclein. Acta neuropathologica, 115, 479-489.
7. Chen, T., Yang, Y., Zhu, S., Lu, Y., Zhu, L., Wang, Y., & Wang, X. (2020). Inhibition of Aβ aggregates in Alzheimer's disease by epigallocatechin and epicatechin-3-gallate from green tea. Bioorganic Chemistry, 105, 104382.
8. Zhang, S., Zhu, Q., Chen, J. Y., OuYang, D., & Lu, J. H. (2020). The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review. Phytomedicine, 79, 153316.
9. Sawda, C., Moussa, C., & Turner, R. S. (2017). Resveratrol for Alzheimer's disease. Annals of the New York Academy of Sciences, 1403(1), 142-149.
10. Lu, C., Guo, Y., Yan, J., Luo, Z., Luo, H. B., Yan, M., ... & Li, X. (2013). Design, synthesis, and evaluation of multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease. Journal of Medicinal Chemistry, 56(14), 5843-5859.
11. Ashrafizadeh, M., Zarrabi, A., Najafi, M., Samarghandian, S., Mohammadinejad, R., & Ahn, K. S. (2020). Resveratrol targeting tau proteins, amyloid-beta aggregations, and their adverse effects: an updated review. Phytotherapy Research, 34(11), 2867-2888.
12. Abdul Manap, A. S., Vijayabalan, S., Madhavan, P., Chia, Y. Y., Arya, A., Wong, E. H., ... & Koshy, S. (2019). Bacopa monnieri, a neuroprotective lead in Alzheimer disease: a review on its properties, mechanisms of action, and preclinical and clinical studies. Drug target insights, 13, 1177392819866412.
13. Saini, N., Singh, D., & Sandhir, R. (2012). Neuroprotective effects of Bacopa monnieri in experimental model of dementia. Neurochemical research, 37, 1928-1937.
14. Kulkarni, P. Bacopa monnieri (Brahmi): A potential treatment course for neurological disorders.
15. Zhang, H. Y., & Tang, X. C. (2006). Neuroprotective effects of huperzine A: new therapeutic targets for neurodegenerative disease. Trends in pharmacological sciences, 27(12), 619-625.
16. Mak, S., Li, W., Fu, H., Luo, J., Cui, W., Hu, S., ... & Han, Y. (2021). Promising tacrine/huperzine A-based dimeric acetylcholinesterase inhibitors for neurodegenerative

disorders: From relieving symptoms to modifying diseases through multitarget. Journal of neurochemistry, 158(6), 1381-1393.
17. Xiao, X., Chen, Q., Zhu, X., & Wang, Y. (2019). ABAD/17β-HSD10 reduction contributes to the protective mechanism of huperzine a on the cerebral mitochondrial function in APP/PS1 mice. Neurobiology of Aging, 81, 77-87.
18. Luo, Y. (2001). Ginkgo biloba neuroprotection: Therapeutic implications in Alzheimer's disease. Journal of Alzheimer's Disease, 3(4), 401-407.
19. Liu, X., Hao, W., Qin, Y., Decker, Y., Wang, X., Burkart, M., ... & Liu, Y. (2015). Long-term treatment with Ginkgo biloba extract EGb 761 improves symptoms and pathology in a transgenic mouse model of Alzheimer's disease. Brain, behavior, and immunity, 46, 121-131.
20. Zhang, X. Z., Qian, S. S., Zhang, Y. J., & Wang, R. Q. (2016). Salvia miltiorrhiza: A source for anti-Alzheimer's disease drugs. Pharmaceutical biology, 54(1), 18-24.
21. Chong, C. M., Su, H., Lu, J. J., & Wang, Y. (2019). The effects of bioactive components from the rhizome of Salvia miltiorrhiza (Danshen) on the characteristics of Alzheimer's disease. Chinese Medicine, 14(1), 19.
22. Ding, B., Lin, C., Liu, Q., He, Y., Ruganzu, J. B., Jin, H., ... & Yang, W. (2020). Tanshinone IIA attenuates neuroinflammation via inhibiting RAGE/NF-κB signaling pathway in vivo and in vitro. Journal of Neuroinflammation, 17(1), 1-17.
23. Im, D. S. (2020). Pro-resolving effect of ginsenosides as an anti-inflammatory mechanism of Panax ginseng. Biomolecules, 10(3), 444.
24. Shin, S. J., Jeon, S. G., Kim, J. I., Jeong, Y. O., Kim, S., Park, Y. H., ... & Moon, M. (2019). Red ginseng attenuates Aβ-induced mitochondrial dysfunction and Aβ-mediated pathology in an animal model of Alzheimer's disease. International Journal of Molecular Sciences, 20(12), 3030.
25. Dar, N. J. (2020). Neurodegenerative diseases and Withania somnifera (L.): An update. Journal of ethnopharmacology, 256, 112769.
26. C Yenisetti, S., & J Manjunath, M. (2015). Neuropharmacological properties of Withania somnifera-Indian Ginseng: An overview on experimental evidence with emphasis on Clinical trials and patents. Recent Patents on CNS Drug Discovery (Discontinued), 10(2), 204-215.
27. Kunle, Oluyemisi, F., Egharevba, Henry, O., Ahmadu, & Peter, O. (2012). Standardization of herbal medicines-A review. International journal of biodiversity and conservation, 4(3), 101-112.
28. Lamichhane, S., Sahariah, B. J., Das, B., Khatiwara, D., Sola, P., Adhikari, R. P., ... & Alam, T. (2023). Herbal Drug Standardization: A Systemic Review. Journal of Drug Delivery and Therapeutics, 13(4), 149-153.
29. Shan, J. J., Rodgers, K., Lai, C., & Sutherland, S. K. (2007, January). Challenges in natural health product research: The importance of standardization. In Proceedings-Western Pharmacology Society (Vol. 50, p. 188). [Western Pharmacology Society]; 1998.
30. Bandaranayake, W. M. (2006). Quality control, screening, toxicity, and regulation of herbal drugs. Modern phytomedicine: turning medicinal plants into drugs, 25-57.
31. Lee, K. M., Jeon, J. Y., Lee, B. J., Lee, H., & Choi, H. K. (2017). Application of metabolomics to quality control of natural product derived medicines. Biomolecules & therapeutics, 25(6), 559.
32. Cavagnaro, J. A. (2002). Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nature Reviews Drug Discovery, 1(6), 469-475.
33. Sadgrove, N. J. (2022). Honest nutraceuticals, cosmetics, therapies, and foods (NCTFs): Standardization and safety of natural products. Critical Reviews in Food Science and Nutrition, 62(16), 4326-4341.
34. Bogunia-Kubik, K., & Sugisaka, M. (2002). From molecular biology to nanotechnology and nanomedicine. Biosystems, 65(2-3), 123-138.
35. Edmundson, M. C., Capeness, M., & Horsfall, L. (2014). Exploring the potential of metallic nanoparticles within synthetic biology. New biotechnology, 31(6), 572-578.